On March 24, 2025, Mangoceuticals Inc. signed a Master Distribution Agreement with Navy Wharf, granting exclusive rights to a nutraceutical product and agreeing to issue 1,000,000 shares and 10% of net sales revenue; additionally, on March 20, 2025, they sold 80,000 shares for $200,000.